High preoperative plasma TIMP-1 is prognostic for early relapse in primary breast carcinoma
✍ Scribed by Paula Kuvaja; Anne Talvensaari-Mattila; Taina Turpeenniemi-Hujanen
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- French
- Weight
- 158 KB
- Volume
- 123
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
TIMP‐1 is a natural inhibitor of extracellular matrix degrading enzymes called matrix metalloproteinases. In addition to its capacity to inhibit matrix degradation, TIMP‐1 has been shown to promote cell growth and inhibit apoptosis. The expression of TIMP‐1 in tumor tissue, as well as in circulating blood, has therefore been shown to associate with worsened survival in several malignancies. In our study, a prospective series of 213 patients with primary breast carcinoma was assessed. Circulating pre‐ and postoperative TIMP‐1 levels were assayed using enzyme‐linked immunosorbent assay analysis. It was shown that high preoperative plasma TIMP‐1 was a powerful predictor of systemic early relapse in breast carcinoma, with HR 8.1 (95% CI 1.8–37.6) (p = 0.007) as a log‐transformed continuous variable in Cox regression univariate analysis. It was shown to be independent of, and superior to, nodal status as a prognostic variable in multivariate analysis, and not associated with any known prognostic clinicopathological parameters. Kaplan‐Meier analysis showed that the patients belonging to the highest quartile of circulating TIMP‐1 levels had a worsened recurrence‐free survival of 79% compared to 94% RFS among patients in the lower quartiles (p = 0.016). The postoperative levels of circulating plasma TIMP‐1 were not found to be prognostic for relapse. In conclusion, preoperative plasma TIMP‐1 was found to be a powerful prognostic factor for early systemic relapse in primary breast carcinoma. © 2008 Wiley‐Liss, Inc.